Best Diversified Pharmaceuticals Companies in United States
The 584 best Diversified Pharmaceuticals companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AbbVie.
Ranking the top Diversified Pharmaceuticals companies across the United States by disclosed equity funding, this directory tracks 584 firms and $42.0B in total disclosed capital. The sector's financial foundation is enormous. Across 42 validated filers, the combined revenue pool hits $211.0B, with a median company revenue of $167M and median growth running at 8% YoY. Pfizer Inc pulled $50.9B in revenue, up 76% year-over-year. AbbVie Inc reached $61.2B, up 9%. Those aren't projections, they're filed figures. The global diversified pharmaceuticals market sat at roughly $2.05T in 2023 and is forecast to reach $3.21T by 2033, compounding at 6.95% annually, driven largely by chronic disease prevalence and rising healthcare expenditure.
So where does the real money concentrate? Net income tells you. Merck & Co. posted $18.3B in net income, 66 times the sector median of $275M. Merck Sharp & Dohme logged $8.0B, 29 times the median. Even if you're tracking smaller players, Gilead leads our directory with $2.6B in disclosed funding, and generic drug approval remains one of the hottest coverage themes shaping competitive dynamics right now. I'd watch regulatory momentum closely here, because approval timelines are the variable that separates median performers from the outsized earners at the top of this list.
- The Business Research Company
Ranked: Best Diversified Pharmaceuticals companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AbbVie Research-based biopharmaceutical company | $23.6B | 92 mo ago | 50,000 | 2012 | Robert Michael CEO | 76 signals Earnings · Capital raise · Announcements | 8,068 patents Immunotherapy antibodies, kinase inhibitor formulations, and novel small‑molecule drug synthesis | — |
| 2 | Gilead Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | $2.6B | 16 mo ago | 4,267 | 1987 | — | 61 signals ▼29% M&A · Earnings · Hiring | — | — |
| 3 | Roivant Sciences Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 91 mo ago | 662 | 2014 | Vivek Ramaswamy Founder | 9 signals ▲29% Funding · Earnings · M&A | — | — |
| 4 | Inhibrx Antibody-based immunotherapeutics for cancer and infectious diseases 45Funding top 25%Patents top 29%Product top 32%Innovation top 33% All 11 signals ▾Fundingtop 25% Patentstop 29% Producttop 32% Innovationtop 33% Techtop 42% Moatbottom 49% Growthbottom 43% Marketbottom 41% Globalbottom 40% Newsbottom 32% Fin. healthbottom 31% Funding: Raised $469M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Patents: 499 patents matched (strict assignee match) · 161 filings since 2022 vs 269 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $469M | 15 mo ago | 112 112 → 111 (-1%) | 2009 | — | — | 499 patents Engineering multispecific therapeutic proteins (antibodies, DR5, serpin fusions) for immune modulation | 1 launch |
| 5 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | 1994 | Garo Armen Chairman & CEO | 10 signals ▼74% Earnings · Announcements · Leadership | — | — |
| 6 | Arrowhead Pharmaceuticals Developer of therapeutics to treat multiple diseases | $290M | 12 mo ago | 427 427 → 809 (+89%) | 1989 | Christopher Anzalone CEO & President | 20 signals ▲67% Earnings · Funding · Contracts | 1,202 patents RNA interference therapeutics targeting disease genes and targeted delivery systems | — |
| 7 | BioXcel Therapeutics Developer of drugs for immune-oncology and neuro-science disorders | $260M | 20 mo ago | 204 | 2017 | — | 6 signals Regulatory · Earnings | 233 patents Non-sedating dexmedetomidine formulations for CNS disorders like depression and agitation | 1 award |
| 8 | Biohaven Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases 72Funding top 19%News top 27%Growth top 30%Market top 40% All 8 signals ▾Fundingtop 19% Newstop 27% Growthtop 30% Markettop 40% Techtop 40% Fin. healthtop 43% Moatbottom 41% Globalbottom 32% Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 13 BI events in 12 mo (of 43 tracked, 9 types) · +86% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $250M | 13 mo ago | 202 | 2022 | — | 13 signals ▲86% Earnings · IPO · Regulatory | — | 1 internship · 1 expansion |
| 9 | Jnana Therapeutics Company developing a drug discovery platform for targeting the solute carrier (SLC) family of transporters | $207M | 43 mo ago | 10 | 2017 | Joanne Kotz Co-Founder & President | — | — | — |
| 10 | Endo International Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines | $171M | 26 mo ago | 2,861 | 1997 | — | — | — | — |
| 11 | Synaptogenix Developer of regenerative therapeutics for neurodegenerative diseases and developmental disorders 40Funding top 16%Patents top 30%Innovation top 31%Moat top 45% All 8 signals ▾Fundingtop 16% Patentstop 30% Innovationtop 31% Moattop 45% Talentbottom 49% Globalbottom 37% Newsbottom 20% Marketbottom 19% Funding: Raised $140M across 12 rounds · 12 rounds over 5 yrs (2.4/yr) Patents: 36 patents matched (strict assignee match) · 34 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $140M | 12 mo ago | 5 | 2012 | Alan Tuchman CEO | — | 36 patents PKC-activating compounds for treating neurodegenerative and nerve‑damage disorders | — |
| 12 | DiaMedica Developing innovative therapies for vascular diseases like preeclampsia and acute ischemic stroke | $122M | 10 mo ago | 16 | 2000 | Rick Pauls President & CEO | 8 signals ▲60% Earnings · Capital raise · Funding | 4 patents Kallikrein-based biologic formulations for diabetes and cardiovascular therapeutic applications | 2 job openings · 1 launch |
| 13 | Cullgen Biopharmaceutical company pioneering targeted protein degradation for innovative medicines | $121M | 37 mo ago | 5 | 2018 | Yue Xiong Co-Founder | — | 4 patents Small‑molecule oncology drugs and targeted protein degraders for cancer therapy | — |
| 14 | EdenRoc R&D company focused on manufacturing of drugs for multiple therapeutic areas | $100M | 19 mo ago | 12 | 2016 | — | — | — | — |
| 15 | FibroBiologics R&D company manufacturing drugs for multiple therapeutic areas | $100M | 6 mo ago | 5 | 2021 | Pete O'Heeron Chairman/CEO/Founder | 6 signals Earnings · Funding | 73 patents Fibroblast-based cell therapies and conditioned media for regenerative and metabolic disorders | — |
| 16 | Imbria Pharmaceuticals Provider of therapeutics solution by translation the cellular metabolism | $90M | 7 mo ago | 4 | 2014 | David-Alexandre Gros Co-Founder & CEO | — | 161 patents Metabolic-modulating small molecules for cardiac, renal, and fibrotic disease therapy | — |
| 17 | Orgenesis Developer of cell and gene therapies for multiple disorders | $79M | 27 mo ago | 167 | 2008 | — | — | 91 patents Cell-based therapeutics and bioprocessing for viral, ocular, and cancer treatments | — |
| 18 | Melt Pharmaceuticals Developer of pharmaceutical products focusing on opioid-free procedural sedation | $77M | 26 mo ago | 5 | 2018 | — | — | — | — |
| 19 | Genentech R&D company focused on manufacturing drugs for multiple therapeutic areas | $72M | 16 mo ago | 13,500 | 1976 | Ashley Magargee Chief Executive Officer | 19 signals ▼90% Hiring · Capital raise · Layoffs | 25,578 patents Therapeutic antibodies, cancer diagnostics, and small‑molecule drug synthesis in biotech | — |
| 20 | Solvetherapeutics.com R&D company focused on manufacturing of antibody drugs for multiple therapeutics areas | $64M | 18 mo ago | 19 | 2020 | Dave Johnson Founder & CEO | — | — | — |
| 21 | Omeros Developing drugs for inflammation, coagulopathies, and disorders of the central nervous system | $63M | 14 mo ago | 276 276 → 224 (-19%) | 1994 | Greg Demopulos Chairman and CEO | 16 signals ▼45% Earnings · Acquisition · M&A | 1,583 patents Therapeutic MASP-1/2/3 inhibitors and complement‑targeting antibodies for disease treatment | — |
| 22 | Viva Tides Manufacturer of oligonucleotides therapeutics | $54M | 2 mo ago | — | 2025 | Keming Zhou Founder & CEO | — | — | — |
| 23 | Seed Therapeutics R&D company focused on manufacturing of drugs for multiple therapeutic areas | $50M | 10 mo ago | 13 | 2019 | Lan Huang Co-founder | — | — | 1 award |
| 24 | Belhaven Biopharma Developer of needle-free nasal spray for anaphylaxis and severe allergic reactions | $44M | 9 mo ago | 4 | 2020 | — | — | 27 patents Dry powder epinephrine formulations for inhalation and intranasal delivery devices | — |
| 25 | Syntrix Biosystems Creating breakthrough medicines through convergent science for immuno-oncology and pain | $41M | 13 mo ago | — | 2002 | John Zebala President and CEO | — | 100 patents CXCR2-modulating small molecules for cancer therapy and pain relief | — |
| 26 | Salubris Biotherapeutics Developer of antibody therapeutics for the treatment of cancer, cardiovascular and metabolic diseases | $35M | 25 mo ago | 1 | 2016 | — | — | 60 patents Recombinant neuregulin‑1 fusion therapeutics for cardiac/fibrosis and anti‑5T4 antibody‑drug conjugates. | — |
| 27 | Animol Discovery R&D company focused on manufacturing drugs for multiple therapeutic areas | $34M | 17 mo ago | 20 | 2019 | Philip Austin Co-founder and Member of Board of Directors | — | 11 patents Veterinary drugs: canine JAK inhibitors and antiparasitic cyclic depsipeptide therapeutics. | — |
| 28 | Bolder BioTechnology Advanced protein engineering for effective, easy-to-use protein therapeutics to improve lives | $31M | 28 mo ago | — | 1997 | George Cox Founder & President | — | 124 patents Enhancing tumor immunogenicity, radioprotective hematopoietic factors, and stem‑cell immunomodulation therapies. | — |
| 29 | Iview therapeutics Specialty company focusing on topical drug and medical device development | $31M | 17 mo ago | 6 | 2015 | Bo Liang Chairman & CEO | — | — | — |
| 30 | Harvard Apparatus Regenerative Technology Biotechnology company using a patient's own stem cells to regenerate organ tissue | $29M | 5 mo ago | 8 | 2012 | Jerry He Chairman and CEO | — | 33 patents Bioengineered scaffolds and devices for in vivo regeneration of hollow tubular organs | — |
| 31 | Cellibre Producer of cellular agricultural products | $25M | 14 mo ago | 26 | 2017 | — | — | 35 patents Microbial cell engineering and enzymatic biosynthesis of cannabinoids and bakuchiol. | — |
| 32 | Nubad Nucleic acid-based drug discovery company developing RNA and DNA-targeted therapeutics | $25M | 14 mo ago | — | 2009 | Dev Arya Founder | — | 6 patents Patents concentrated in chemistry & materials | — |
| 33 | Neutrolis R&D company focused on manufacturing of drugs for multiple therapeutic areas | $23M | 15 mo ago | 9 | 2017 | Abdul Hakkim Co-Founder | — | 91 patents Engineered DNase enzymes for therapeutic and industrial nucleic acid degradation applications | — |
| 34 | Repair Biotechnologies Developer of protein & gene therapies for treatment of aging diseases | $20M | 7 mo ago | 6 | 2018 | Bill Cherman Co-founder and Chairman | — | 20 patents Metabolic engineering of cholesterol pathways and liver cancer therapeutics | — |
| 35 | Trailhead Biosystems Developer of cell therapies for the treatment of multiple diseases | $17M | 5 mo ago | 13 | 2015 | Jan Jensen Co-Founder & CEO | — | 96 patents Stem cell differentiation protocols for therapeutic blood, neural, and pancreatic cells | 1 launch |
| 36 | Pin Therapeutics Developer of small molecule based therapeutics for the treatment of several diseases | $15M | 17 mo ago | 14 | 2017 | Hyunsun Jo Co-Founder & CEO | — | — | — |
| 37 | Orthogon Therapeutics Developing a pipeline of therapeutics for a range of disease indications | $12M | 2 mo ago | 3 | 2012 | Ali Munawar Founding CEO | — | — | — |
| 38 | Orphagen Pioneering small molecule therapies for cancer and inflammatory bowel disease | $12M | 18 mo ago | 7 | 2001 | — | — | — | — |
| 39 | Parion Sciences Developing therapies to restore lung mucosal defense for respiratory diseases | $12M | 10 mo ago | 13 | 2000 | Paul Boucher CEO and President | — | 546 patents Respiratory therapeutics targeting ENaC inhibition and mucolytic agents for airway clearance | — |
| 40 | Thetis Pharma Clinical-stage pharmaceutical company pioneering Resolvin E1 therapeutics for inflammatory diseases and cancer | $11M | 14 mo ago | 3 | 2011 | Gary Mathias Co-Founder & CEO | — | — | — |
| 41 | Sequome Provider of decodes and designs sequences to develop sequence medicines | $11M | 11 mo ago | — | 2022 | Eeshit Vaishnav Founder & CEO | — | — | — |
| 42 | Revel Pharmaceuticals Diversified pharmaceutical company | $10M | 23 mo ago | 5 | 2019 | David Spiegel Co-Founder | — | — | 1 job opening |
| 43 | Artery Therapeutics Developing peptide therapeutics for neurodegenerative diseases and cardiovascular disease | $9M | 13 mo ago | — | 2004 | Jan Johansson President & CEO | — | — | — |
| 44 | Mandalmed Developing therapies for fibrosis by modulating glycobiology and innate immunity | $6M | 22 mo ago | 5 | 2000 | Constance John Founder & CEO | — | 14 patents Patents concentrated in health & consumer products | — |
| 45 | MAKScientific Targeting the endocannabinoid system for the treatment of metabolic disorders, pain, addiction, and… | $6M | 13 mo ago | — | 2004 | Alexandros Makriyannis Co-Founder | — | 22 patents Therapeutic small‑molecule drugs and formulations for addiction, cannabinoid toxicity, and fibrosis | — |
| 46 | Nuvox Pharma Developer of platform-based oxygen therapeutics for human conditions | $4M | 21 mo ago | 10 | 2008 | Evan Unger President and CEO | — | — | — |
| 47 | AcePre Developer of therapeutics and health resources focused on disease management | $3M | 21 mo ago | 7 | 2017 | Daping Fan Founder | — | — | — |
| 48 | DFH Pharma Developer of pharmaceutical products, focusing on drug development and medical trends | $2M | 8 mo ago | — | 2011 | Carl Wild Founder & CEO | — | — | — |
| 49 | Steel Therapeutics Manufacturer of pharmaceutical products for multiple therapeutic areas | $2M | 18 mo ago | 4 | 2020 | Allen Phillips Co-Founder | — | — | — |
| 50 | Cadrebioscience R&D company focused on manufacturing drugs for multiple therapeutic areas | $1M | 13 mo ago | 4 | 2019 | — | — | — | — |
Top 12 Diversified Pharmaceuticals companies in United States
#1
Series A · Woburn, Massachusetts · founded 2025$54Mraised▾
Manufacturer of oligonucleotides therapeutics. It specializing in developing extrahepatic RNA-targeting therapeutics. The company aims to overcome traditional limitations by delivering siRNA and antisense oligonucleotides to tissues beyond the liver, such as muscles and the nervous system, for treating chronic diseases.
- Apr 2026Series A$54M
#2
Acquired · Foster City, California · founded 1987 · 4267 employees$2.6Braised▾
Gilead is a developer of medicines to treat HIV/AIDS, liver diseases, cancer & others. It is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. It has developed many medicines such as Lenacapavir capsid inhibitor (GS-6207) for HIV, Long-acting treatment: 2 bNAbs (GS-5423, GS-2872), Selgantolimod TLR-8 agonist (GS-9688), PD-L1 inhibitor (GS-4224) HBV cure, and many more. In 2022, the company recorded annual revenues of $27.28B and a net profit of $4.59B.
- Jan 2025Post IPO$290K
- Jul 2020Grant (prize money)$82M
- Jan 2020Grant (prize money)—
- Apr 2017Post IPO$1.2M
#3
Public · Lexington, Massachusetts · founded 1994 · 533 employees$440.7Mraised▾
Developer of immunotherapies to treat cancer. The company's portfolio consists of bio-engineered therapies targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
- Jun 2025Post IPO—
- Jul 2020Post IPO$35M
- Jan 2019Post IPO$30M
- Oct 2018Post IPO$40M
#4
Series A · Braintree, Massachusetts · founded 2012 · 3 employees$12.5Mraised▾
Developing a pipeline of therapeutics for a range of disease indications
- Apr 2026Series A$11M
- Dec 2024Series A$5.2M
- Nov 2021Series A$8M
- Mar 2018Series A$4.4M
#5
Series B · Boston, Massachusetts · founded 2014 · 4 employees$90.2Mraised▾
Imbria Pharmaceuticals provides therapeutics solution by translation the cellular metabolism. It is involved in providing transformative medicine, by altering the cellular metabolism and mitochondrial function.
- Nov 2025Series B—
- Mar 2025Series B$66.7M
- Jul 2019Series B$50M
- Jul 2018Series B$40.2M
#6
Public · Houston, Texas · founded 2021 · 5 employees$100Mraised▾
R&D company manufacturing drugs for multiple therapeutic areas
#7
Public · Holliston, Massachusetts · founded 2012 · 8 employees$28.5Mraised▾
HRGN is a clinical-stage biotechnology company that specializes in regenerating organ tissue using a patient's own stem cells grown on a scaffold. They are focused on developing innovative solutions for patients with damaged organs due to cancer, trauma, birth defects, or other diseases. The company is led by an experienced team with a background in biotechnology, patient care, finance, and new product development.
- Dec 2025Post IPO$700K
- Jul 2025Post IPO$2M
- Apr 2024Post IPO$1.5M
- Apr 2023Post IPO$6M
#8
Acquired · Pasadena, California · founded 1989 · 427 employees$290.2Mraised▾
Developer of therapeutics to treat multiple diseases. The company develops medicines that treat intractable diseases by silencing the genes that cause them. The company’s pipeline includes ARO-AAT to treat liver diseases, ARO-APOC3 for Hypertriglyceridemia, ARO-ANG3 for Dyslipidemia, and more.
- May 2025Grant (prize money)$305K
- Dec 2017Post IPO$7.2M
- Jan 2017Post IPO$9.7M
- Sep 2016Post IPO$56.5M
#9
Acquired · Solana Beach, California · founded 2009 · 112 employees$468.6Mraised▾
Antibody-based immunotherapeutics for cancer and infectious diseases. it has proprietary platforms that enable fit-for-function bio-therapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. Its product pipeline includes INBRX-109 an engineered tetravalent sdAb-based therapeutic candidate to induce tumor selective programmed cell death, and INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 to treat locally advanced or metastatic solid tumors.
- Mar 2025Grant (prize money)$120.1K
- Sep 2023Post IPO$200M
- Feb 2021Grant (prize money)$279.4K
- Apr 2020Conventional Debt$10M
#10
Public · Minneapolis, Minnesota · founded 2000 · 16 employees$121.9Mraised▾
Developing innovative therapies for vascular diseases like preeclampsia and acute ischemic stroke. The company is focused on improving the lives of individuals battling serious vascular diseases by developing innovative therapies that reduce ischemia. With a focus on preeclampsia and acute ischemic stroke, they are dedicated to advancing patient care through a novel approach that centers around improving blood flow to ischemic tissue to improve patient outcomes. Their investigational drug candidate is intended to restore normal levels of a naturally occurring protein, which is intended to allow patients to naturally regulate their blood flow and maintain vascular homeostasis as well as reduce inflammation and oxidative stress. They are conducting clinical trials to explore the safety and effectiveness of their drug candidate. This research aims to address significant unmet medical needs in treating stroke patients and pregnancy complications.
- Jul 2025Post IPO$30.1M
- Jun 2024Post IPO$11.8M
- Jun 2023Post IPO$37.5M
- Apr 2023Post IPO$750K
#11
Series B · Beachwood, Ohio · founded 2015 · 13 employees$16.7Mraised▾
Developer of cell therapies for the treatment of multiple diseases. The company uses HD-DoE technology platform to develop a pipeline for diabetes, cancer, bone marrow, Huntington's disease, and more.
- Jan 2026Series B$20M
- May 2025Series B$20M
- Oct 2022Series A$10M
- Nov 2020Series A$6.6M
#12
Public · Michigan · founded 2012 · 5 employees$140.1Mraised▾
Developer of regenerative therapeutics for neurodegenerative diseases and developmental disorders. It focuses on discovering and developing targeted, novel regenerative therapeutics. The company's pipeline includes synaptogenic treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s disease, Fragile X Syndrome, MS, Parkinsons, Traumatic Brain Injury, Stroke, and Autism Spectrum Disorders. It leverages Bryostatin-1 and its analogues for therapeutic development.
- Jun 2025Post IPO$5.5M
- Sep 2024Post IPO$3.2M
- Nov 2022Post IPO$15M
- Jun 2021Post IPO$12.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.